Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer

This publication has 33 references indexed in Scilit:

• Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
  Journal of Clinical Oncology, 1997
• 653: Response to chemotherapy is the first prognostic factor in metastatic breast cancer
  European Journal of Cancer, 1997
• Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
  Annals of Oncology, 1997
• Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study
  European Journal of Cancer, 1996
• Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
  Journal of Clinical Oncology, 1996
• Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?
  Breast Cancer Research and Treatment, 1989
• Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
  Journal of Clinical Oncology, 1987
• Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s
  Cancer, 1985
• Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
  Cancer, 1977
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958